ztimelines

Development Timelines

The following estimate of short-term and mid-term corporate milestones
is based on the current development status of the technology. The actual
timing of each step will be dependent upon discussions with the FDA on
the variables and clinical indications that will be acceptable to the
Agency. This model predicts that the LINC technology can be taken
through Phase-IIb clinicals in less than five years if previously tested
PTHrP or PPAR gamma compounds are developed for fibrotic disease.

Year	Expenses	Timeline
2004	$ 1.5 million	LINC Pharmaceuticals begins
2005	$2.7 million	LINC conducts R&D / P-I clinicals
2006	$ 4.8 million	LINC conducts Phase-II clinicals
2007	$ 6.6 million	LINC conducts Phase-II clinicals
2008	$ 8.5 million	LINC conducts Phase-II clinicals
2009	TBD	Corporate partner / Phase-III
2010	TBD	Corporate partner / Phase-III
2011	TBD	Corporate partner / Phase-III